Food and Drug Administration (FDA)

Pfizer Fails to End Lawsuit Over Bextra, Celebrex Safety

Vetter's Newest Facility Successfully Completes FDA Inspection

Biogen Wins EU Backing for Big New MS Drug Hope

Antibiotics Crisis Prompts Rethink on Risks, Rewards

Jury Orders J&J Unit to Pay $8.3 Million in Metal Hip Trial

Pfizer Gets Celebrex Patent Extension

Switzerland's Roche Pledges to Open Up Access to Drug Data

FDA Halts Trials of Amgen Drug in Children, Cites Death

Affymax, Takeda Recall Anemia Drug Omontys After Deaths

GSK Vaccine Ingredient Scrutinized for Narcolepsy Clues

Boehringer Ingelheim Ohio Subsidiary Enters Consent Decree

FDA Head, Company CEOs Cheer Bumper Haul of New Drugs

U.S. Government Investment Gives Flu Vaccines a Shot in the Arm

Roche Says US Allows it to Tap Adult Tamiflu Reserves

Drug Industry Bets on New Blockbusters in 2013

Genetically Modified Food Labeling Measure to Qualify for Washington State Ballot

US FDA New Drug Approvals Hit 16-Year High in 2012

FDA Approves Bristol Myers, Pfizer's Anti-Clotting Drug Eliquis

Number of New Drugs Picks Up in Europe and U.S.

U.S. Supreme Court to Review Lawsuits over Flaws in Generic Drugs

Ranbaxy Halts Generic Lipitor Production After Recall

India's Ranbaxy Recalls Generic Lipitor in U.S.

Roche Offers Compromise in Flu Drug Row

Social Media in Pharmaceutical Companies

Novartis CEO Says U.S. Plant Gets FDA Clearance

Drugmaker Boehringer Settles Marketing Claim for $95 Million

ThromboGenics Says Main Drug Cleared for U.S. Launch

FDA Reviewers Spot Safety Concerns With Sanofi, Isis Lipid Drug

More Drugs May Be Linked to US Meningitis Outbreak

How Compounding Pharmacies Rallied Patients to Fight Regulation

U.S. FDA Cracks Down on Thousands of Websites for Selling Fake Drugs

U.S. Finds No Wrongdoing in Yasmin Patent Settlement

Atox Bio to Seek Funds by Year-End for More Trials

FDA Approves Teva Version of Amgen's Neupogen

Watson Sues FDA on Generic Diabetes Drug Ruling

50 more articles

Top-Feature

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

BIO Deutschland e.V.

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Expert Insights

ADCs for Precision Cancer Therapy

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.